Wyeth kills off Solvay pact

Following bifeprunox's FDA rejection in August, Wyeth has opted out of its development deal with Solvay. In order to gain approval, the FDA told Wyeth and Solvay that they must run another trial and present more data before the agency would reconsider approval. Apparently Wyeth wanted no part in that. The company is returning rights to bifeprunox, as well as several other drug candidates. Wyeth and Solvay first announced their partnership in 2004 and then expanded it in 2007 to include research in neuroscience.

According to Wyeth's statement, the company "terminated the collaboration with Solvay after assessing the opportunity for bifeprunox and determining it would not have sufficient commercial value for the two companies to share."

- see this release

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.